search
Back to results

A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN) (upliFT-D)

Primary Purpose

Frontotemporal Dementia

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
PBFT02
Sponsored by
Passage Bio, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Frontotemporal Dementia focused on measuring frontotemporal dementia, Progranulin Mutations, FTD-GRN, Gene Therapy, Dementia Gene Therapy, AAV1, Fronto-temporal Dementia

Eligibility Criteria

35 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Documented to be a pathogenic GRN mutation carrier
  2. Clinical diagnosis of frontotemporal dementia
  3. Have a reliable informant / caregiver (and back-up informant / caregiver) who personally speaks with or sees the subject at least weekly
  4. Living in the community (i.e., not in a nursing home); assisted living may be permitted at the discretion of the investigator

Exclusion Criteria:

  1. Classification of the GRN mutation as "not pathogenic," "likely benign variant," "benign variant," or "pathogenic nature unclear"
  2. Previous treatment with any gene therapy. Any other therapies with the potential to alter PGRN levels must be washed out for at least 5 half-lives prior to entry into this study
  3. Homozygous GRN mutation carrier
  4. Rosen-modified Hachinski Ischemic Scale score > 7
  5. Known presence of a structural brain lesion (eg, tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic subject
  6. Known presence of an AD-causing mutation in PSEN1, PSEN2 or APP based on genetic testing history (if performed)
  7. Previous history of Korsakoff encephalopathy, severe alcohol or substance dependence (within 5 years of onset of dementia), except where onset of increased alcohol consumption occurs at the time of FTD disease onset
  8. History of untreated vitamin B12 deficiency
  9. Presence of untreated hypothyroidism (thyroid stimulating hormone [TSH] > ULN and free T4 < LLN)
  10. eGFR ≤ 30 ml/min (as calculated using the CKD-EPI equation)
  11. Alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 2 × ULN, or total bilirubin > ULN)
  12. Respiratory failure that requires supplemental oxygen
  13. Inability to provide full consent or the lack of a legally authorized caregiver with adequate contact who can provide consent
  14. Any contraindication to MRI or lumbar puncture (LP) (eg, local infection, history of thrombocytopenia, coagulopathy)
  15. Any contraindication to the ICM administration procedure
  16. Medical conditions or laboratory or vital sign abnormalities that would increase risk of complications from intra-cisterna magna injection, anesthesia, LP, and/or MRI (e.g., fever, hypoxia, tachycardia, or evidence of active infection)
  17. Immunocompromised status
  18. Peripheral axonal sensory neuropathy
  19. Receipt of a vaccine within 14 days of dosing
  20. A positive test result for human immunodeficiency virus (HIV), human T cell leukemia virus (HTLV) type 1 or type 2, or Hepatitis B or C; a Mycobacterium tuberculosis positive test within 1 year of or determined at screening
  21. Malignant neoplasia (except localized skin cancer) or a documented history of hereditary cancer syndrome
  22. Any concurrent disease that, in the opinion of the investigator, may cause cognitive impairment unrelated to GRN mutations, including other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin deficiency
  23. Current or recent history of clinically significant suicidal ideation within the past 6 months
  24. For females of childbearing potential, a positive serum pregnancy test at the screening visit, a positive serum result on Day 1 prior to administration of the investigational product, or unwillingness to have additional pregnancy tests during the study. Females of childbearing potential must use a highly effective method of birth control or engage in abstinence until 90 days postdose
  25. Women who are breastfeeding
  26. For sexually active men, unwillingness to use a medically accepted method of double-barrier contraception (such as a condom/diaphragm used with spermicide) or engage in abstinence from the date of screening until 90 days postdose
  27. Any condition (eg, history of any disease, evidence of any current disease, any finding upon physical examination, or any laboratory abnormality) that, in the opinion of the investigator, would put the subject at undue risk or would interfere with evaluation of the investigational product or interpretation of subject safety or study results
  28. Any acute illness requiring hospitalization within 30 days of enrollment
  29. Failure to meet the protocol-specified coagulation test criteria:

    • Platelet count over 100,000 per uL
    • INR less than 1.5
    • aPTT less than 40 seconds
  30. Use of anticoagulants in the 2 weeks prior to screening, or anticipated use of anticoagulants during the study. Antiplatelet therapies may be acceptable
  31. Hypersensitivity or contraindications to corticosteroid use
  32. Known or suspected intolerance or hypersensitivity to PBFT02 or any of its ingredients or to closely related compounds

Sites / Locations

  • University of PennsylvaniaRecruiting
  • University of Texas at HoustonRecruiting
  • Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG)Recruiting
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP)Recruiting
  • Montreal Neurological Institute-Hospital
  • University of Toronto
  • Besta Institute
  • Centro Hospitalar e Universitário de Coimbra

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Cohort 1

Cohort 2

Optional Cohort 3

Arm Description

Drug: PBFT02 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBFT02, via intra cisterna magna *GC/g: gene copy per gram of estimated brain weight

Drug: PBFT02 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna *GC/g: gene copy per gram of estimated brain weight

Drug: PBFT02 Dose 3: 2.2 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna *GC/g: gene copy per gram of estimated brain weight

Outcomes

Primary Outcome Measures

Number of Participants with Treatment-Related AEs and SAEs
Assess the number of treatment-related adverse events (AEs) and serious adverse events (SAEs)
Change in Nerve Conduction Velocity from Baseline on Nerve Conduction Studies
Assess changes in nerve conduction velocity in the distal segments of the sural, radial, and median sensory nerves and peroneal motor nerve as measured on conventional nerve conduction studies.
Change in Nerve Conduction Amplitude from Baseline on Nerve Conduction Studies
Assess changes in nerve conduction amplitude in the distal segments of the sural, radial, and median sensory nerves and peroneal motor nerve as measured on conventional nerve conduction studies.
Assess Humoral Response Against the Vector and Transgene in Serum
Assess serum antibody titers against AAV1 and against progranulin following ICM administration of PBFT02
Assess Humoral Response Against the Vector and Transgene in CSF
Assess antibody titers in the cerebrospinal fluid against AAV1 and against progranulin following ICM administration of PBFT02

Secondary Outcome Measures

Change from baseline in FTD clinical domains as assessed by the Clinical Dementia Rating National Alzheimer's Coordinating Center frontotemporal lobar degeneration domains (CDR Plus NACC FTLD)
Assess changes in cognitive, behavioral and language domains using the CDR Plus NACC FTLD
Change from baseline in neurocognitive and other assessments
Assess changes using the Multilingual Naming Test (MINT).
Change from baseline in neurocognitive and other assessments
Assess changes using the Number Span Test
Change from baseline in neurocognitive and other assessments
Assess changes using Verbal Fluency
Change from baseline in neurocognitive and other assessments
Assess changes using Semantic Fluency
Change from baseline in neurocognitive and other assessments
Assess changes using the Trail Making Test A and B
Change from baseline in neurocognitive and other assessments
Assess changes using California Verbal Learning Test (CVLT)
Change from baseline in neurocognitive and other assessments
Assess changes using the Benson Complex Figure Copy (immediate and delayed recall)
Change from baseline in neurocognitive and other assessments
Assess changes using the Montreal Cognitive Assessment (MoCA)
Change from baseline in neurocognitive and other assessments
Assess changes using the Frontotemporal Dementia Rating Scale (FRS)
Change from baseline in neurocognitive and other assessments
Assess changes using the Cambridge Behavioral Inventory - Revised (CBI-R)
Change from baseline in neurocognitive and other assessments
Assess changes using the Clinical Global Impression of Severity and Change (CGI-S, CGI-C)
Change in Biomarkers of Progranulin Levels in Plasma
Assess change in progranulin levels in plasma when compared with baseline
Change in Biomarkers of Progranulin Levels in CSF
Assess change in progranulin levels in CSF when compared with baseline
Change in Concentration of Biomarkers of Disease Progression in Plasma
Assess changes in neurofilament light chain (NfL) concentration and glial fibrillary acidic protein (GFAP) as markers for neurodegeneration and disease progression in plasma
Change in Concentration of Biomarker of Disease Progression in CSF
Assess change in neurofilament light chain concentration (NfL) as a marker for neurodegeneration and disease progression in CSF
Change in Ocular Biomarkers of Disease Progression
Assess changes in retinal thickness and retinal lipofuscin assessed by optical coherence tomography as markers of disease progression
Change in Brain Anatomy as Assessed by MRI
Assess change in brain volume by MRI imaging
Change in Brain Anatomy as Assessed by MRI
Assess change in cortical thickness by MRI imaging
Change in Brain Anatomy as Assessed by MRI
Assess change in white matter integrity by MRI imaging
Change in Activities of Daily Living Scales
Assess change in activities of daily living as measured by the Schwab and England Activities of Daily Living Scale
Change in Activities of Daily Living Scales
Assess change in activities of daily living as measured by the Functional Activities Questionnaire
Change in Survival
Assess change in vital status

Full Information

First Posted
February 2, 2021
Last Updated
September 18, 2023
Sponsor
Passage Bio, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04747431
Brief Title
A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)
Acronym
upliFT-D
Official Title
A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the Cisterna Magna of Adult Subjects With Frontotemporal Dementia and Mutations in the Progranulin Gene
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 14, 2021 (Actual)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
August 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Passage Bio, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment in patients with frontotemporal dementia and mutations in the progranulin gene (FTD-GRN).
Detailed Description
PBFT02 is an adeno-associated viral vector serotype 1 carrying GRN, the gene encoding for human progranulin, formulated as a solution for injection into the cisterna magna. This is a global interventional, multicenter, open-label, single-arm, dose-escalation study of PBFT02 delivered as a one-time dose administered into the cisterna magna to patients with FTD-GRN. Subjects aged ≥ 35 and ≤ 75 years with early symptomatic FTD-GRN may be enrolled into the study. Two dose levels of PBFT02 will be studied in patients with FTD-GRN. The study will sequentially enroll 2 cohorts. An optional third dose level cohort may be enrolled based on the results of the first two cohorts. This is a 5-year study, with a 2-year main study, followed by a 3-year safety extension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Frontotemporal Dementia
Keywords
frontotemporal dementia, Progranulin Mutations, FTD-GRN, Gene Therapy, Dementia Gene Therapy, AAV1, Fronto-temporal Dementia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
Open-label, multi-center, dose escalation
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
Drug: PBFT02 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBFT02, via intra cisterna magna *GC/g: gene copy per gram of estimated brain weight
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
Drug: PBFT02 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna *GC/g: gene copy per gram of estimated brain weight
Arm Title
Optional Cohort 3
Arm Type
Experimental
Arm Description
Drug: PBFT02 Dose 3: 2.2 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna *GC/g: gene copy per gram of estimated brain weight
Intervention Type
Drug
Intervention Name(s)
PBFT02
Intervention Description
PBFT02
Primary Outcome Measure Information:
Title
Number of Participants with Treatment-Related AEs and SAEs
Description
Assess the number of treatment-related adverse events (AEs) and serious adverse events (SAEs)
Time Frame
Up to 5 years (multiple visits)
Title
Change in Nerve Conduction Velocity from Baseline on Nerve Conduction Studies
Description
Assess changes in nerve conduction velocity in the distal segments of the sural, radial, and median sensory nerves and peroneal motor nerve as measured on conventional nerve conduction studies.
Time Frame
From baseline to 5 years (multiple visits)
Title
Change in Nerve Conduction Amplitude from Baseline on Nerve Conduction Studies
Description
Assess changes in nerve conduction amplitude in the distal segments of the sural, radial, and median sensory nerves and peroneal motor nerve as measured on conventional nerve conduction studies.
Time Frame
From baseline to 5 years (multiple visits)
Title
Assess Humoral Response Against the Vector and Transgene in Serum
Description
Assess serum antibody titers against AAV1 and against progranulin following ICM administration of PBFT02
Time Frame
Up to 5 years (multiple visits)
Title
Assess Humoral Response Against the Vector and Transgene in CSF
Description
Assess antibody titers in the cerebrospinal fluid against AAV1 and against progranulin following ICM administration of PBFT02
Time Frame
Up to 5 years (multiple visits)
Secondary Outcome Measure Information:
Title
Change from baseline in FTD clinical domains as assessed by the Clinical Dementia Rating National Alzheimer's Coordinating Center frontotemporal lobar degeneration domains (CDR Plus NACC FTLD)
Description
Assess changes in cognitive, behavioral and language domains using the CDR Plus NACC FTLD
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using the Multilingual Naming Test (MINT).
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using the Number Span Test
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using Verbal Fluency
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using Semantic Fluency
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using the Trail Making Test A and B
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using California Verbal Learning Test (CVLT)
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using the Benson Complex Figure Copy (immediate and delayed recall)
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using the Montreal Cognitive Assessment (MoCA)
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using the Frontotemporal Dementia Rating Scale (FRS)
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using the Cambridge Behavioral Inventory - Revised (CBI-R)
Time Frame
From baseline to 2 years (multiple visits)
Title
Change from baseline in neurocognitive and other assessments
Description
Assess changes using the Clinical Global Impression of Severity and Change (CGI-S, CGI-C)
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Biomarkers of Progranulin Levels in Plasma
Description
Assess change in progranulin levels in plasma when compared with baseline
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Biomarkers of Progranulin Levels in CSF
Description
Assess change in progranulin levels in CSF when compared with baseline
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Concentration of Biomarkers of Disease Progression in Plasma
Description
Assess changes in neurofilament light chain (NfL) concentration and glial fibrillary acidic protein (GFAP) as markers for neurodegeneration and disease progression in plasma
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Concentration of Biomarker of Disease Progression in CSF
Description
Assess change in neurofilament light chain concentration (NfL) as a marker for neurodegeneration and disease progression in CSF
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Ocular Biomarkers of Disease Progression
Description
Assess changes in retinal thickness and retinal lipofuscin assessed by optical coherence tomography as markers of disease progression
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Brain Anatomy as Assessed by MRI
Description
Assess change in brain volume by MRI imaging
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Brain Anatomy as Assessed by MRI
Description
Assess change in cortical thickness by MRI imaging
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Brain Anatomy as Assessed by MRI
Description
Assess change in white matter integrity by MRI imaging
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Activities of Daily Living Scales
Description
Assess change in activities of daily living as measured by the Schwab and England Activities of Daily Living Scale
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Activities of Daily Living Scales
Description
Assess change in activities of daily living as measured by the Functional Activities Questionnaire
Time Frame
From baseline to 2 years (multiple visits)
Title
Change in Survival
Description
Assess change in vital status
Time Frame
From baseline to 2 years (multiple visits)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Documented to be a pathogenic GRN mutation carrier Clinical diagnosis of frontotemporal dementia Have a reliable informant / caregiver (and back-up informant / caregiver) who personally speaks with or sees the subject at least weekly Living in the community (i.e., not in a nursing home); assisted living may be permitted at the discretion of the investigator Exclusion Criteria: Classification of the GRN mutation as "not pathogenic," "likely benign variant," "benign variant," or "pathogenic nature unclear" Previous treatment with any gene therapy. Any other therapies with the potential to alter PGRN levels must be washed out for at least 5 half-lives prior to entry into this study Homozygous GRN mutation carrier Rosen-modified Hachinski Ischemic Scale score > 7 Known presence of a structural brain lesion (eg, tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic subject Known presence of an AD-causing mutation in PSEN1, PSEN2 or APP based on genetic testing history (if performed) Previous history of Korsakoff encephalopathy, severe alcohol or substance dependence (within 5 years of onset of dementia), except where onset of increased alcohol consumption occurs at the time of FTD disease onset History of untreated vitamin B12 deficiency Presence of untreated hypothyroidism (thyroid stimulating hormone [TSH] > ULN and free T4 < LLN) eGFR ≤ 30 ml/min (as calculated using the CKD-EPI equation) Alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 2 × ULN, or total bilirubin > ULN) Respiratory failure that requires supplemental oxygen Inability to provide full consent or the lack of a legally authorized caregiver with adequate contact who can provide consent Any contraindication to MRI or lumbar puncture (LP) (eg, local infection, history of thrombocytopenia, coagulopathy) Any contraindication to the ICM administration procedure Medical conditions or laboratory or vital sign abnormalities that would increase risk of complications from intra-cisterna magna injection, anesthesia, LP, and/or MRI (e.g., fever, hypoxia, tachycardia, or evidence of active infection) Immunocompromised status Peripheral axonal sensory neuropathy Receipt of a vaccine within 14 days of dosing A positive test result for human immunodeficiency virus (HIV), human T cell leukemia virus (HTLV) type 1 or type 2, or Hepatitis B or C; a Mycobacterium tuberculosis positive test within 1 year of or determined at screening Malignant neoplasia (except localized skin cancer) or a documented history of hereditary cancer syndrome Any concurrent disease that, in the opinion of the investigator, may cause cognitive impairment unrelated to GRN mutations, including other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin deficiency Current or recent history of clinically significant suicidal ideation within the past 6 months For females of childbearing potential, a positive serum pregnancy test at the screening visit, a positive serum result on Day 1 prior to administration of the investigational product, or unwillingness to have additional pregnancy tests during the study. Females of childbearing potential must use a highly effective method of birth control or engage in abstinence until 90 days postdose Women who are breastfeeding For sexually active men, unwillingness to use a medically accepted method of double-barrier contraception (such as a condom/diaphragm used with spermicide) or engage in abstinence from the date of screening until 90 days postdose Any condition (eg, history of any disease, evidence of any current disease, any finding upon physical examination, or any laboratory abnormality) that, in the opinion of the investigator, would put the subject at undue risk or would interfere with evaluation of the investigational product or interpretation of subject safety or study results Any acute illness requiring hospitalization within 30 days of enrollment Failure to meet the protocol-specified coagulation test criteria: Platelet count over 100,000 per uL INR less than 1.5 aPTT less than 40 seconds Use of anticoagulants in the 2 weeks prior to screening, or anticipated use of anticoagulants during the study. Antiplatelet therapies may be acceptable Hypersensitivity or contraindications to corticosteroid use Known or suspected intolerance or hypersensitivity to PBFT02 or any of its ingredients or to closely related compounds
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patient/Family Inquiries
Phone
267-866-0113
Email
patientservices@passagebio.com
First Name & Middle Initial & Last Name or Official Title & Degree
Physician Inquiries
Email
medinfo@passagebio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tiffini Voss, MD
Organizational Affiliation
Passage Bio, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dahlia Kamel
Email
Dahlia.kamel@pennmedicine.upenn.edu
Facility Name
University of Texas at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Omar Hasan
Phone
713-486-2647
Email
omar.hasan@uth.tmc.edu
Facility Name
Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG)
City
Minas Gerais
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leonardo Cruz de Souza, MD
Email
leocruzsouza@hotmail.com
Facility Name
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP)
City
São Paulo
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luzia Lima Carreira
Phone
55 11 2661.6723
Email
luzia.carreira@hc.fm.usp.br
Facility Name
Montreal Neurological Institute-Hospital
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H3A 2B4
Country
Canada
Individual Site Status
Active, not recruiting
Facility Name
University of Toronto
City
Toronto
Country
Canada
Individual Site Status
Not yet recruiting
Facility Name
Besta Institute
City
Milan
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Centro Hospitalar e Universitário de Coimbra
City
Coimbra
Country
Portugal
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)

We'll reach out to this number within 24 hrs